The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study demonstrated that clopidogrel plus aspirin was superior to aspirin alone for prevention of recurrent vascular events in patients with acute coronary syndromes. The aim of this study was to compare the effect of these two regimens on biochemical markers of platelet and coagulation activation.
Introduction
Platelets play a central role in the pathogenesis of acute coronary syndromes. Disruption of atherosclerotic plaque exposes thrombogenic material in the lipid-rich core of the plaque to the blood, causing platelet adhesion and activation and thrombin generation. Activated platelets undergo shape change, release of vasoactive and procoagulant substances, and conformational change of the surface membrane glycoprotein IIb/IIIa receptor which allows fibrinogen cross-linking and platelet aggregation [1] . The modified membrane of activated platelets also provides a phospholipid surface on which activated coagulation factors assemble, thereby amplifying thrombin generation. The resulting intracoronary thrombus can impair coronary blood flow which causes myocardial ischemia and the clinical manifestations of unstable angina or acute myocardial infarction [1, 2] . Aspirin is an effective antiplatelet agent, reducing the risk of myocardial infarction, stroke, and cardiovascular death by about 25% in a broad category of patients with arterial thrombosis [3] . More recently, the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study demonstrated that the addition of clopidogrel to aspirin was associated with a further 20% reduction in the risk of death, myocardial infarction or stroke in patients with acute coronary syndromes (Relative risk [RR] 0·80; 95% CI: 0·72-0·90; P<0·001) [4] . The antithrombotic effect of aspirin is mediated through inhibition of platelet cyclooxygenase which not only irreversibly blocks platelet function but also inhibits platelet-dependent thrombin generation [5] [6] [7] . In contrast, clopidogrel exerts its antithrombotic effect by selectively and irreversibly inhibiting ADP-induced platelet aggregation [8, 9] . Because aspirin and clopidogrel target different pathways of platelet activation, the combination of clopidogrel and aspirin appears to be more effective than aspirin alone for suppression of platelet activation as measured by platelet aggregometry [10, 11] . However, it is uncertain whether the addition of clopidogrel to aspirin suppresses coagulation activation and thrombin generation.
In the present study, we compared the effects of combined clopidogrel and aspirin with aspirin alone on blood markers of platelet and coagulation activation in a subset of patients randomized into the CURE study [4, 12] . Our primary objective was to determine whether clopidogrel plus aspirin was more effective than aspirin alone in suppressing platelet and coagulation activation in patients with acute coronary syndromes.
Methods

Patients
The CURE study [4, 12] was an international, randomized, placebo-controlled trial comparing clopidogrel with placebo in aspirin-treated patients with non-ST-elevation acute coronary syndrome. A total of 12 562 patients hospitalized within 24 h of onset of symptoms were randomized to clopidogrel (300 mg loading dose followed by 75 mg daily) or placebo for a period of 3-12 months. All patients were treated with aspirin (recommended dose 75-325 mg daily). Patients with ST segment elevation, at high risk of bleeding, with a contraindication to anticoagulant or antiplatelet therapy, requiring long-term oral anticoagulation, or who underwent coronary revascularization within the previous 3 months were not eligible for inclusion. At the time of randomization, the investigator was required to state whether the patient also was entering the coagulation study. Centres participating in the coagulation study were selected based on their ability to collect blood samples according to the required quality control standards, and investigators at these sites were encouraged to enrol consecutive patients into the coagulation study. The Ethics Review Committees of the participating hospitals approved the study and all patients provided informed consent.
Blood collection and processing
Blood was drawn from an antecubital vein by clean venipuncture using a 21-gauge needle without a tourniquet. Blood samples were collected at baseline (the time of randomization), 7 days after randomization or hospital discharge (whichever occurred first), and at 30 5 days after randomization. At each of these time points, blood was drawn into two 5 ml vacutainer tubes prefilled with 0·5 ml of 3·2% buffered sodium citrate (Becton Dickinson, Ontario, Canada). The blood collection tubes were kept on ice for a maximum of 30 min before centrifugation at 1700 g for 15 min at room temperature. The resultant platelet-poor plasma was harvested and subjected to a second centrifugation to ensure complete removal of platelets. Platelet-free plasma was harvested and frozen in aliquots at 40 to 70 C prior to shipment on dry ice or in liquid nitrogen to the central laboratory at the Hamilton Civic Hospitals Research Centre in Canada where they were stored at 70 C until analysed.
Laboratory analyses
Commercially available immunoassay kits were used to measure plasma levels of P-selectin (R & D Systems, Minneapolis, U.S.A.) as a marker of platelet activation, prothrombin fragment F1.2 (Behring Diagnostics, Marburg, Germany) as a marker of thrombin generation, D-dimer (Diagnostic Stago, Asnieres, France) as a marker of endogenous fibrinolysis, and von Willebrand factor (Affinity Biologicals, Hamilton, Canada) as a marker of both platelet and endothelial cell activation. Analyses were performed by laboratory staff blinded to treatment allocation. All samples were analysed in the Haemostasis Reference Laboratory at the Hamilton Civics Hospitals Research Centre in Hamilton, Canada.
Statistical analyses
Means or proportions for baseline demographics and cardiovascular risk factors were calculated for patients randomized to clopidogrel or placebo. The significance of any difference in means was tested using Student's t-test, and the significance of any difference in proportions was tested using a chi square test. Because the values of laboratory assays were skewed, geometric means were calculated after log transformation of the raw data and the significance of any differences was tested using Student's t-test. In the overall study cohort, the change in blood levels of platelet and coagulation activation from baseline to day 7, and from baseline to day 30 were compared using a mixed model approach with adjustment of the P-value for multiple comparisons using Tukey's method [13] . Where a normal distribution could not be approximated by log transformation, the Wilcoxon's rank-sum test was used to examine the significance of differences between the two groups.
A logistic regression model was used to examine the association between blood levels of platelet and coagulation activation markers at baseline, day 7, and day 30, and the change in levels of blood markers dichotomized as above or below the median from baseline to day 7 and from baseline to day 30, and the risk of cardiovascular death, myocardial infarction, stroke or refractory ischaemic by the end of the study. We also assessed the independent contribution of blood levels of platelet and coagulation markers to these outcomes by using a multivariable regression model that adjusted for age, gender, and differences in baseline prognostic factors.
All P-values are two-sided and confidence intervals are calculated at the 95% level.
Results
Patients
A total of 485 patients were entered into the CURE coagulation study from 23 centres in Canada (n=14) and Poland (n=9).
Baseline characteristics
There were no significant differences in baseline characteristics between patients randomized to clopidogrel (n=246) and placebo (n=239) ( Table 1) nor were there important differences between patients entered into the coagulation substudy (n=485) and the overall CURE study (n=12 562) ( Table 2 ). In the coagulation substudy, the mean age of patients was 64·3 years and approximately one-half were males. The mean time from onset of symptoms to study entry was 12·9 h. More than 90% of patients had ECG changes and approximately one-quarter had myocardial infarction without ST elevation at the time of presentation. The majority of patients were receiving heparin (71·3%) and aspirin (61·4%) prior to randomization. More than 95% received heparin and all patients received aspirin post-randomization.
Comparison of markers in patients receiving clopidogrel plus aspirin compared with aspirin alone
Blood levels of platelet and coagulation activation markers in patients receiving clopidogrel plus aspirin compared with aspirin alone at baseline, day 7, and day 30 are presented in Table 3 . Patients receiving clopidogrel plus aspirin compared with aspirin alone had similar baseline geometric mean plasma levels of P-selectin (50·2 vs 51·7 ng . ml 1 , P=0·45), prothrombin fragment F1.2 (1·13 vs 1·12 nmol . l 1 , P=0·94), D-dimer (467 vs 460 ng . ml 1 , P=0·85), and von Willebrand factor levels (1·89 vs 1·85 U . ml 1 , P=0·59) (Fig. 1 ). There also were no significant differences between the two treatment groups in blood levels of these markers at day 7 or day 30 (Table 3 ) or in the magnitude of the change in blood markers from baseline to day 7 or day 30 between the two treatment groups (data not shown).
Comparison of markers at day 7 and day 30 with baseline in the overall coagulation study cohort
Blood levels of platelet and coagulation activation markers in the overall coagulation study cohort at baseline, day 7, and day 30 are presented in Table 4 . P-selectin levels (normal range (NR) 11-55 ng . ml 1 ) were within the laboratory normal range at baseline (50·9 ng . ml 1 . Von Willebrand factor levels (NR 0·50-1·70 U . ml 1 ) were elevated at baseline (1·87 U . ml 1 ; 95% CI: 1·80-1·94 U . ml 1 ), were significantly higher compared with baseline at day 7 (2·00 vs 1·87 U . ml 1 , P<0·0001), and remained elevated at day 30 (1·78 U . ml 1 ; 95% CI: 1·71-1·85 U . ml 1 ) (Fig. 2) . 
Association between blood markers and clinical outcomes
Seventy-eight of the 485 patients included in the coagulation CURE study (16·1%) experienced the composite outcome of cardiovascular death, myocardial infarction, stroke or refractory ischaemia by the end of the study (Table 5) . A similar event rate for this outcome was seen in the overall CURE study cohort (2222/12 562, 17·7%). Blood levels of D-dimer and von Willebrand factor at baseline, day 7, and day 30 appeared to be consistently higher in patients who experienced the composite outcome cardiovascular death, myocardial infarction, stroke or refractory ischaemia by the end of the study compared with those who did not, and were statistically significantly different at day 7. Similarly, blood levels of prothrombin fragment F1.2 at day 7 and day 30 appeared to be higher in patients who experienced the composite outcome compared with those who did not, although these differences did not achieve statistical significance. The magnitude of the increase in blood levels of prothrombin fragment F1.2, D-dimer, and von Willebrand factor between baseline and day 7 and between baseline and day 30 also appeared to be greater in patients who experienced the composite outcome cardiovascular death, myocardial infarction, stroke or refractory ischaemia by the end of the study compared with those who did not. There was no association between blood levels or change in blood levels of P-selectin during the study and clinical outcome.
In a logistic regression model that adjusted for age, gender, and baseline prognostic factors, an increase in prothrombin fragment F1.2 levels above the median between day 1 and day 7 was independently associated with the primary composite outcome of cardiovascular death, myocardial infarction, stroke, or refractory ischaemia at the end of the study (OR 2·0; 95% CI: mean values for P-selectin, prothrombin fragment F1.2, D-dimer, and 1·1-3·5). However, due to the relatively small numbers of outcome events (n=78) this analysis was underpowered to reliably detect an independent association between other coagulation markers and clinical outcome.
Discussion
This study indicates that in aspirin-treated patients with non-ST elevation acute coronary syndromes, clopidogrel is no more effective than placebo for suppressing blood markers of coagulation activation. The significant rise in blood markers of thrombin generation (prothrombin fragment F1.2) and endogenous fibrinolysis (D-dimer) at day 7 and day 30 compared with baseline was not attenuated by the addition of clopidogrel to aspirin and was greatest in patients who experienced cardiovascular death or a recurrent ischaemic event by the end of the study. Von Willebrand factor levels remained elevated throughout the study period, likely reflecting ongoing endothelial cell activation. Our results demonstrating an association between elevated blood markers of coagulation activation and recurrent clinical ischaemic events are consistent with previous reports [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Short-term treatment with unfractionated heparin, low-molecular-weight heparin, or direct thrombin inhibitors, can suppress blood markers [15] [16] [17] [18] [19] [20] [21] [22] , but (re-) elevation occurs following cessation of therapy [20] [21] [22] [23] , which supports the concept that longer duration antithrombotic therapy may be required to pacify the thrombus. However, despite the superiority of more intensive and longer-duration antiplatelet therapy with clopidogrel plus aspirin compared with aspirin alone, there was no measurable impact of the addition of clopidogrel on blood levels of platelet or coagulation activation markers.
There are several potential alternative explanations for our findings. First, it is possible that low-risk patients with less marked platelet and coagulation activation were entered into the CURE coagulation study, thereby limiting the statistical power of our study to detect a difference in blood markers between the two groups. However, baseline characteristics as well as clinical event rates were similar in patients entered into the coagulation study compared with the overall CURE study, indicating that our patients were representative of the overall CURE population. Furthermore, our coagulation study is one of the largest performed to date in patients with unstable angina and was adequately powered to reliably detect a modest 15-20% relative difference between in blood levels between the two treatment groups. Therefore, lack of statistical power is unlikely to account for our findings.
Second, suboptimal specimen handling can cause in-vitro platelet or coagulation activation, leading to an artifactual rise in blood markers in both treatment groups and obscuring any difference between them, thereby biasing the study toward the null hypothesis of no difference. However, we employed standardized and rigorous procedures for blood collection, processing, and specimen transport, and centres were selected for inclusion in the present study based on their previously demonstrated ability to comply with the quality control requirements of coagulation study protocols [23] . Therefore, this also is unlikely to account for the lack of an observed effect of clopidogrel on blood markers of platelet or coagulation activation.
Third, although elevated blood levels of P-selectin have been reported in patients with acute coronary syndromes [25] [26] [27] [28] , this rise appears to be only transient with blood levels returning to normal within several hours of the onset of symptoms [28] . Because the mean duration of time between onset of symptoms and entry into the coagulation substudy was approximately 12 h, we may have failed to detect an early transient rise in soluble P-selectin levels. Reports of a poor correlation between blood level of P-selectin and platelet membrane P-selectin expression [29] further support the possibility that soluble P-selectin levels in the blood are not a sensitive marker of platelet activation during long-term follow-up. However, soluble P-selectin levels in the blood may also have been suppressed by aspirin therapy since more than 60% of patients were taking aspirin at the time of the baseline blood sample and more than 95% were taking aspirin at days 7 and 30.
The lack of a measurable effect of clopidogrel on blood markers of coagulation activation is not entirely unexpected given the indirect effect of platelets on promoting thrombin generation. In addition, there are several alternative pathways by which platelets can be activated which are not blocked by clopidogrel or aspirin. Von Willebrand factor or collagen that is exposed on damaged subendothelial surfaces following plaque rupture can cause platelet activation, while circulating agonists such as adrenaline and, in particular, thrombin, further activate platelets. Clopidogrel and aspirin do not block these pathways of platelet activation. Meanwhile, the lack of a differential effect of combined antiplatelet therapy compared with aspirin 
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alone on coagulation activation markers is consistent with recent reports indicating no effect of combined glycoprotein IIb/IIIa receptor antagonist plus aspirin compared with aspirin alone on blood markers of thrombin generation in patients with acute coronary syndromes [30, 31] .
In conclusion, our results indicate that the clinical benefits of clopidogrel when added to aspirin are unrelated to an effect on the blood markers of platelet and coagulation activation measured in our study. The persistence of coagulation activation and thrombin generation despite long-term clopidogrel and aspirin therapy suggests that even more intensive antithrombotic therapy may be required in this patient population. 
